Biocon Q1 Core Operations Shine

  Published 8 months ago

Biocon’s Q1 FY26 saw core EBITDA grow 11% YoY, with strong biosimilars and CRDMO growth offsetting one-time gains.

  • Biosimilars revenue jumped 18% YoY to Rs 2,458 crore, fueled by strong demand and new product launches globally.
  • CRDMO business grew 11% in revenue and 19% in EBITDA, driven by pilot programs converting into long-term contracts.
  • Operating revenue rose 15% YoY to Rs 3,942 crore, reflecting broad-based growth across biosimilars, generics, and research services.

You might like these

India's Forex Reserves Dip $1.2B in Week

Punjab & Sind Q1 Profit Jumps 51%

Aditya Birla AMC Q1 Profit Up 18%

eClerx Jumps on Strong Q1, Nomura Boost

Barbeque-Nation Renamed Amid Q1 Loss

ERGS-I Transmission Project Summary

Enviro Infra Engineers Expands Renewable & EPC Projects

News that matters the most ⚡